Bell, R; Brown, J; Parmar, M; Toi, M; Suter, T; Steger, GG; Pivot, X; ... Cameron, D; + view all Bell, R; Brown, J; Parmar, M; Toi, M; Suter, T; Steger, GG; Pivot, X; Mackey, J; Jackisch, C; Dent, R; Hall, P; Xu, N; Morales, L; Provencher, L; Hegg, R; Vanlemmens, L; Kirsch, A; Schneeweiss, A; Masuda, N; Overkamp, F; Cameron, D; - view fewer (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Annals of Oncology , 28 (4) pp. 754-760. 10.1093/annonc/mdw665.

Preview	Text Parmar-Ann Oncol Accepted_1.pdf - Accepted Version Download (153kB) | Preview
Preview	Other (Figure) Parmar_fig S1-Ann Oncol_2.pdf - Accepted Version Download (401kB) | Preview
Preview	Other (Figure) Parmar_fig S2-Ann Oncol_3.pdf - Accepted Version Download (450kB) | Preview
Preview	Other (Table) Parmar_table 1-Ann Oncol_4.pdf - Accepted Version Download (69kB) | Preview
Preview	Other (Table) Parmar_table S1-Ann Oncol_5.pdf - Accepted Version Download (89kB) | Preview
Preview	Other (Table) Parmar_table S2-Ann Oncol_6.pdf - Accepted Version Download (14kB) | Preview
Preview	Other (Table) Parmar_table S3-Ann Oncol_7.pdf - Accepted Version Download (75kB) | Preview
Preview	Other (Table) Parmar_table S4-Ann Oncol_8.pdf - Accepted Version Download (71kB) | Preview
Preview	Other (Figure) Parmar_Figure1 Ann Oncol_9.pdf - Accepted Version Download (506kB) | Preview
Preview	Other (Figure) Parmar_Figure2 Ann Oncol_10.pdf - Accepted Version Download (446kB) | Preview

Abstract

PURPOSE: To assess the long-term impact of adding bevacizumab to adjuvant chemotherapy for early triple-negative breast cancer (TNBC). METHODS: Patients eligible for the open-label randomized phase III BEATRICE trial had centrally confirmed triple-negative operable primary invasive breast cancer (pT1a-pT3). Investigators selected anthracycline- and/or taxane-based chemotherapy for each patient. After definitive surgery, patients were randomized 1:1 to receive ≥4 cycles of chemotherapy alone or with 1 year of bevacizumab (5 mg/kg/week equivalent). Stratification factors were nodal status, selected chemotherapy, hormone receptor status, and type of surgery. The primary end point was invasive disease-free survival (IDFS; previously reported). Secondary outcome measures included overall survival (OS) and safety. RESULTS: After 56 months' median follow-up, 293 of 2591 randomized patients had died. There was no statistically significant difference in OS between treatment arms in either the total population (hazard ratio 0.93, 95% confidence interval [CI] 0.74-1.17; P = 0.52) or pre-specified subgroups. The 5-year OS rate was 88% (95% CI 86-90%) in both treatment arms. Updated IDFS results were consistent with the primary IDFS analysis. Five-year IDFS rates were 77% (95% CI 75-79%) with chemotherapy alone versus 80% (95% CI 77-82%) with bevacizumab. From 18 months after first study dose to study end, new grade ≥3 adverse events occurred in 4.6% and 4.5% of patients in the two arms, respectively. CONCLUSION: Final OS results showed no significant benefit from bevacizumab therapy for early TNBC. Late-onset toxicities were rare in both groups. Five-year OS and IDFS rates suggest that the prognosis for patients with TNBC is better than previously thought.ClinicalTrials.gov: NCT00528567.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item